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http://dx.doi.org/10.1053/j.gastro.2016.07.039BACKGROUND & AIMS: The best regimen to re-treat patients
who do not respond to direct-acting antivirals (DAAs) and the
feasibility of further shortening regimens is unclear. We
assessed the efﬁcacy and safety of the combination of the
nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor
velpatasvir, and the NS3/4A protease inhibitor GS-9857 in
patients with hepatitis C virus genotype 1 infection.METHODS:
We performed an open-label trial at 32 sites in the United States
and at 2 sites in New Zealand of 197 patients with genotype 1
hepatitis C virus infection, with or without compensated
cirrhosis, who were treatment-naive or were treated previously
with a DAA. Between March 2, 2015, and September 1, 2015,
patients received sofosbuvir-velpatasvir (400 mg/100 mg in a
ﬁxed-dose combination) plus GS-9857 (100 mg) once daily for
6–12 weeks, plus ribavirin for 1 treatment group consisting of
treatment-naive patients with cirrhosis. The primary end point
was sustained virologic response 12 weeks after treatment
(SVR12). RESULTS: Among treatment-naive patients without
cirrhosis, 71% (24 of 34; 95% conﬁdence interval [CI], 53–85)
achieved SVR12 after 6 weeks of treatment and 100% (36 of 36;
95% CI, 90%–100%) achieved SVR12 after 8 weeks of treat-
ment. Among treatment-naive patients with cirrhosis, 94%
(31 of 33; 95% CI, 80–99) achieved SVR12 after 8 weeks of
treatment and 81% (25 of 31; 95% CI, 63–93) achieved SVR12
after 8 weeks of treatment with ribavirin. Among
DAA-experienced patients treated for 12 weeks, 100% without
cirrhosis (31 of 31; 95% CI, 89–100) and 100% with cirrhosis
(32 of 32; 95% CI, 89–100) achieved SVR12. The most common
adverse events were headache, diarrhea, fatigue, and nausea.
One patient (<1%) discontinued treatment because of adverse
events. CONCLUSIONS: In a phase 2 open-label trial, we found 8
weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to
be safe and effective in treatment-naive patients; 12 weeks wassafe and effective in patients previously treated with DAAs. The
combination was safe and effective in patients with or without
compensated cirrhosis. Clinicaltrials.gov no: NCT02378935.Keywords: Direct-Acting Antiviral Agent; NS5A; NS5B; NS3/4A.
f the 6 known genotypes of the hepatitis C virusO(HCV), genotype 1 is the most common, affecting
almost half of the estimated 130–150 million people with
chronic HCV infection worldwide.1,2 Although genotype 1
HCV was long considered the most difﬁcult to treat HCV
infection, several highly effective and safe regimens involving
combinations of recently approved direct-acting antivirals
(DAAs) now are available for patients with genotype 1 HCV,
regardless of treatment history and stage of liver disease.3–6
One clinical question that remains unanswered is the iden-
tiﬁcation of retreatment regimens for patients who do not
achieve sustained virologic response (SVR) with approved
regimens of DAAs in which resistance-associated sub-
stitutions (RASs) may have emerged. Treatment-emergent
RASs, particularly after exposure to NS5A inhibitors, have
the potential to limit re-treatment options.7 There is
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LIVERcurrently no approved regimen for patients who have failed
an HCV regimen including an NS5A inhibitor. Current treat-
ment recommendations for NS5A inhibitor-experienced pa-
tients suggest delaying therapy in those without urgent
indications for treatment and, when treatment is necessary,
long durations with the addition of ribavirin often are
advised on the basis of minimal evidence.8 One possible
strategy to address the need for a salvage regimen is to
combine highly potent DAAs with enhanced activity against
RASs. Such a combination regimen additionally may allow for
shortening of treatment duration in patients who have not
been treated previously for HCV.
Sofosbuvir is a nucleotide analogue inhibitor of the HCV
NS5B polymerase approved for the treatment of genotypes
1–6 HCV infection in combination with other agents.9,10
Velpatasvir is a novel HCV NS5A inhibitor with pan-
genotypic efﬁcacy.11 The combination of sofosbuvir and
velpatasvir has been shown in phase 3 clinical trials to be
highly effective and safe in treatment-naive and previously
treated patients with HCV of all genotypes, including those
with compensated and decompensated cirrhosis.12–14
GS-9857 is a novel macrocyclic NS3/4A protease inhibitor
with potent in vitro antiviral activity against genotypes 1–6
HCV and broad coverage of NS3/4A protease poly-
morphisms, including RASs associated with ﬁrst-generation
NS3/4A protease inhibitors.15,16 In a phase 1 trial, admin-
istration of 100 mg of GS-9857 to patients with genotypes
1–4 HCV resulted in median maximum reductions in
HCV-RNA levels of 3 log10 IU/mL or greater.
17
We assessed the efﬁcacy and safety of 6–12 weeks of
sofosbuvir-velpatasvir plus GS-9857 in treatment-naive
patients and patients previously treated with DAA-
containing regimens with genotype 1 HCV, including those
with compensated cirrhosis.Materials and Methods
Study Design
This open-label, 2-cohort, phase 2 study was conducted
between March 2, 2015, and September 1, 2015, at 32 sites in
the United States and at 2 sites in New Zealand. Cohort 1
enrolled treatment-naive patients, and cohort 2 enrolled
patients previously treated with regimens that contained an
NS5A inhibitor alone, or 2 or more classes of DAAs.
Cohort 1. At the time the study was initiated, 2 groups of
treatment-naive patients were enrolled in cohort 1: a group of
patients without cirrhosis, who received sofosbuvir-velpatasvir
plus GS-9857 for 6 weeks, and a group of patients with
cirrhosis, who received sofosbuvir-velpatasvir plus GS-9857 for
8 weeks. The protocol speciﬁed that if the rate of relapse among
patients with cirrhosis who received 8 weeks of treatment was
10% or less, there was an option that another group could be
enrolled to receive 6 weeks of treatment. This option was not
exercised. Instead, preliminary results from these ﬁrst 2
groups prompted us to amend the protocol to add 2 groups to
this cohort: a group of patients without cirrhosis, who
received 8 weeks of sofosbuvir-velpatasvir plus GS-9857, and a
group of patients with cirrhosis, who received 8 weeks of
sofosbuvir-velpatasvir plus GS-9857 with ribavirin.Cohort 2. Two groups of DAA-experienced
patients—those with and without cirrhosis—were enrolled in
cohort 2. Both groups received 12 weeks of sofosbuvir-
velpatasvir plus GS-9857. The protocol speciﬁed that if the
rate of relapse in either group was 10% or less, there was an
option that another group of patients could be enrolled to
receive 8 weeks of treatment. This option was not exercised.
Patients. Enrollment was open to patients at least 18 years
of age chronically infected with genotype 1 HCV with serum HCV
levels of at least 10,000 IU/mL. Cirrhosis was deﬁned as any one
of the following: biopsy showing cirrhosis (Metavir score of 4 or
Ishak score of 5), transient elastography (FibroScan; Echosens,
Paris, France) result greater than 12.5 kPa, or a FibroTest
(Biopredictive, Paris, France) score greater than 0.75 together
with an aspartate aminotransferase–to-platelet ratio index
greater than 2 during screening. Exclusion criteria included a
platelet count less than 50,000 cells/mL, hemoglobin level less
than 110 g/L for women and less than 120 g/L for men, albumin
level less than30 g/L, creatinine clearance less than60mL/min as
calculated by the Cockcroft–Gault equation, and prothrombin
time or direct bilirubin greater than 1.5 times the upper limit of
normal. Patients with evidence of decompensation (ie, clinical
ascites, encephalopathy, or variceal hemorrhage) and those with
hepatocellular carcinoma were excluded.
Written informed consent was obtained from all patients
before enrollment and before any study procedures were per-
formed. The study was approved by the institutional review
board or independent ethics committee at all participating sites
and was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice. The sponsor
(Gilead Sciences) collected the data, monitored the study
conduct, and performed the statistical analyses. All authors had
access to the study data and reviewed and approved the ﬁnal
manuscript.Procedures
All patients received a ﬁxed-dose combination tablet of
sofosbuvir 400 mg and velpatasvir 100 mg once daily, along
with a 100-mg tablet of GS-9857 once daily, taken with food.
Ribavirin was administered 1000–1200 mg/day (1000 mg for
patients weighing <75 kg and 1200 mg for patients weighing
75 kg) in a divided daily dose. This was an open-label study,
in which patients were enrolled by investigators at the study
centers. No participants or study personnel were blinded to
treatment assignments at any time during the study.Assessments
Serum HCV-RNA concentrations were measured using the
COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 (Roche,
Indianapolis, IN) with a lower limit of quantiﬁcation for HCV
RNA of less than 15 IU/mL. HCV genotype and subtype were
determined using the Siemens Versant HCV Genotype INNO-
LiPA 2.0 assay (Tarrytown, NY). For all patients, the inter-
leukin 28B genotype was determined by polymerase chain
reaction ampliﬁcation and sequencing of the rs12979860
single-nucleotide polymorphism.
Deep sequencing of the NS3A, NS5A, and NS5B regions of
the HCV RNA using MiSeq technology (DDL Diagnostic Labo-
ratory, Rijswijk, The Netherlands) was performed at baseline
for all patients and at the time of virologic failure for all
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Rpatients who did not achieve SVR 12 weeks after treatment
(SVR12). The resulting sequences were compared with refer-
ence sequences or sequences from baseline samples to deter-
mine the prevalence of RASs and the association of RASs with
virologic outcomes. RASs present at greater than 1% and 15%
of sequence reads were reported, unless speciﬁed.
Safety was assessed in all patients at all on-treatment visits
and for 30 days after the completion of treatment by physical
examination and review of adverse events and laboratory test
results.
Outcomes
The primary efﬁcacy end point of this study was SVR12
(serum HCV-RNA level <15 IU/mL) in all patients who were
enrolled and received at least 1 dose of study drug. The sec-
ondary efﬁcacy end points included the proportion of patients
with virologic failure. The primary safety end point was any
adverse event leading to the permanent discontinuation of
study treatment.
Statistical Analysis
For this exploratory phase 2 study we did not plan or
conduct any inferential statistics. No formal sample size cal-
culations were used to determine the group size of 30. The
SVR12 rate in each of the treatment groups was calculated with
2-sided 95% exact conﬁdence intervals (CIs) based on the
Clopper–Pearson method.
Role of the Funding Source
The study sponsor oversaw trial management, data collec-
tion, statistical analyses, and the writing and review of the
report. All authors had access to the study data and had
reviewed and approved the ﬁnal manuscript.
Results
Of the 247 patients screened, 197 were enrolled and
received treatment: 34 treatment-naive patients without
cirrhosis, 33 treatment-naive patients with cirrhosis, 31
previously treated patients without cirrhosis, and 32 pre-
viously treated patients with cirrhosis (Supplementary
Figure 1). Reasons for screen failure are listed in the
Appendix. Baseline characteristics of patients are shown in
Table 1. The groups were balanced overall with regard to
baseline characteristics. A majority of patients in all groups
were men, of white race, with genotype 1a infection and
non-CC interleukin 28B genotypes. Among the DAA-
experienced patients in cohort 2, 46% previously received
a NS5A inhibitor (ledipasvir, n ¼ 7; daclatasvir, n ¼ 11;
other, n ¼ 11) and 54% previously received a NS3/4A
protease inhibitor and a NS5B polymerase inhibitor
(simeprevir with sofosbuvir, n ¼ 25; other, n ¼ 9).
By week 4 of treatment, 68 of 70 (97%) treatment-naive
patients without cirrhosis and 60 of 64 (94%) treatment-
naive patients with cirrhosis had HCV-RNA levels less than
15 IU/mL. Among treatment-experienced patients, 29 of 31
(94%) without cirrhosis and 31 of 32 (97%) with cirrhosis
had HCV-RNA levels less than 15 IU/mL by week 4 of
treatment. By week 8 of treatment, all patients receiving atleast 8 weeks of treatment had a HCV-RNA level less than
15 IU/mL. In treatment-naive patients with cirrhosis, the
addition of ribavirin appeared to have no impact on HCV
viral kinetics (Table 2).
Among treatment-naive patients without cirrhosis, rates
of SVR12 were 71% (24 of 34; 95% CI, 53–85) in patients
receiving 6 weeks of treatment, and 100% (36 of 36; 95%
CI, 90–100) in patients receiving 8 weeks of treatment
(Table 2). Among treatment-naive patients with cirrhosis,
rates of SVR12 were 94% (31 of 33; 95% CI, 80–99) in
patients receiving 8 weeks of sofosbuvir-velpatasvir plus
GS-9857 and 81% (25 of 31; 95% CI, 63–93) in patients
receiving 8 weeks of sofosbuvir-velpatasvir plus GS-9857
with ribavirin (Table 2). Among patients previously
treated with DAA-containing regimen(s), rates of SVR12
were 100% (31 of 31; 95% CI, 89–100) in patients without
cirrhosis receiving 12 weeks of treatment, and 100% (32 of
32; 95% CI, 89–100) in patients with cirrhosis receiving 12
weeks of treatment. Across the groups, no signiﬁcant dif-
ferences in SVR12 rates were observed based on baseline
differences (Appendix). Eighteen patients with virologic
failure relapsed after the end of treatment; no patient had a
virologic breakthrough during treatment (Appendix).
Baseline sequencing was available for 197 of the 197
patients enrolled in the study. Overall, 63% (84 of 134) of
treatment-naive and 83% (52 of 63) of DAA-experienced
patients had baseline class RASs in at least 1 of the 3 target
genes (NS3, NS5A, and NS5B), with a 1% deep sequencing
assay cut-off level (Table 3). Among the DAA-experienced
patients, 93% (27 of 29) of the NS5A inhibitor-experienced
patients had NS5A RASs, as compared with 21% (7 of 34) of
DAA-experienced patients who were not treated previously
with an NS5A inhibitor (data not shown).
Table 3 shows the SVR rates for patients without RASs
and with single and multiclass NS3, NS5A, and NS5B RASs
with a 1% sequencing cut-off level. In treatment-naive pa-
tients, 8 weeks of treatment with sofosbuvir-velpatasvir
plus GS-9857 without ribavirin led to SVR12 in 96% (23
of 24) and 98% (44 of 45) of patients without and with
baseline RASs, respectively. Use of a 15% sequencing cut-off
level led to a similar result (Supplementary Material). All
DAA-experienced patients, regardless of the presence of
single or multiclass RASs, achieved SVR12 after 12 weeks of
treatment with sofosbuvir-velpatasvir plus GS-9857. There
were 12 DAA-experienced patients with the NS5A RAS
Y93H/N at baseline, all of whom achieved SVR12.
Sequencing data were available for all 18 treatment-naive
patients who relapsed. Eleven of 18 patients (61%) had the
same number of or fewer RASs at the time of virologic relapse
than at baseline. Four of 18 patients (22%) had no RASs both
at baseline and at virologic relapse. Only 3 patients had
treatment-emergent RASs, all in the NS3 gene and all at fre-
quencies less than 2% of the viral population. The treatment-
emergent NS3 RASs included V170T, Q41R/A156T, and
V36M. Of these, only A156T resulted in in vitro resistance to
GS-9857 (confers an w500-fold shift in median effective
concentration in genotype 1a and 1b replicon assays).
The most common adverse events were headache,
nausea, fatigue, and diarrhea (Table 4). Overall, 64% of
Table 1.Baseline Characteristics
Treatment naive DAA experienced
No cirrhosis Cirrhosis No cirrhosis Cirrhosis
SOF-VEL plus
GS-9857 for
6 wk (n ¼ 34)
SOF-VEL plus
GS-9857 for
8 wk (n ¼ 36)
SOF-VEL plus
GS-9857 for
8 wk (n ¼ 33)
SOF-VEL plus
GS-9857 plus RBV
for 8 wk (n ¼ 31)
SOF-VEL plus
GS-9857 for
12 wk (n ¼ 31)
SOF-VEL plus
GS-9857 for
12 wk (n ¼ 32)
Age, y 53 51 58 59 57 59
Men 23 (68) 21 (58) 19 (58) 19 (61) 23 (74) 26 (81)
Race
White 31 (91) 32 (89) 25 (76) 26 (84) 27 (87) 26 (81)
Black 3 (9) 4 (11) 7 (21) 5 (16) 4 (13) 6 (19)
Hawaiian or Paciﬁc Islander 0 0 1 (3) 0 0 0
Mean BMI, kg/m2 (SD) 26.1 (4.64) 27.4 (5.94) 28.9 (4.64) 29.2 (6.48) 26.4 (3.92) 32.0 (6.07)
HCV RNA level, log10 IU/mL 6.2 (0.51) 6.2 (0.55) 6.0 (0.59) 6.3 (0.47) 6.4 (0.77) 6.0 (0.61)
HCV genotype
1a 27 (79) 28 (78) 26 (79) 25 (81) 27 (87) 24 (75)
1b 7 (21) 8 (22) 7 (21) 6 (19) 4 (13) 8 (25)
IL28b
CC 12 (35) 9 (25) 7 (21) 12 (39) 4 (13) 4 (13)
CT 15 (44) 21 (58) 19 (58) 12 (39) 19 (61) 21 (66)
TT 7 (21) 4 (11) 7 (21) 6 (19) 7 (23) 7 (22)
Missing 0 2 (6) 0 1 (3) 1 (3) 0
Baseline ALT level, U/L (SD) 61 (34.8) 57 (43.6) 97 (49.0) 95 (68.3) 59 (41.4) 84 (54.1)
DAA experience
NS5A inhibitor with or without
other DAA(s)
NA NA NA NA 17(55) 12 (38)
Ledipasvir NA NA NA NA 5 (16) 2 (6)
Daclatasvir NA NA NA NA 5 (16) 6 (19)
Other NA NA NA NA 7 (23) 4 (13)
NS3/4A protease
inhibitor and NS5B
polymerase inhibitor
NA NA NA NA 14 (45) 20 (62)
Sofosbuvir-simeprevir NA NA NA NA 8 (26) 17 (53)
Other NA NA NA NA 6 (19) 3 (9)
BMI, body mass index; IL, interleukin; NA, not applicable; RBV, ribavirin; SOF-VEL, sofosbuvir-velpatasvir.
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Rpatients experienced at least 1 adverse event. Patients in the
ribavirin-containing group had higher rates of fatigue (32%)
and anemia (23%) than patients in the other groups. Two
patients, both in the group of treatment-naive patients with
cirrhosis receiving 8 weeks of treatment without ribavirin,
had treatment-emergent serious adverse events: a 61-year-
old white woman with valvular disease experienced atrial
ﬂutter on day 35 of treatment, and a 67-year-old white
woman had vertigo on post-treatment day 26.
One patient discontinued treatment because of adverse
events. This patient, a 50-year-old black woman with
cirrhosis who was receiving sofosbuvir-velpatasvir plus GS-
9857 with ribavirin, stopped study treatment on day 24
after having conﬁrmed abnormally high levels of alanine
aminotransferase (ALT) (grade 3) and aspartate amino-
transferase (grade 2). A single grade 1 increase in total
bilirubin was observed at study treatment week 2, and
remained within normal limits at all other timepoints.
Aminotransferase levels returned to normal 4 weeks after
stopping the study drug. An evaluation for acute causes of
hepatitis was negative. Another patient in the same treat-
ment group discontinued ribavirin after experiencing diar-
rhea, nausea, vomiting, and rib soreness on day 2 of
treatment. This patient continued sofosbuvir-velpatasvir
plus GS-9857 without ribavirin and achieved SVR12.
One treatment-naive patient with cirrhosis who received
8 weeks of treatment died on day 175 of follow-up
evaluation. The cause of death was atypical pneumonia.
Overall, 19 patients (10%) had grade 3 laboratory
abnormalities and 2 patients (1%) had grade 4 laboratory
abnormalities. Grades 3 and 4 laboratory abnormalities
occurred almost exclusively in patients with cirrhosis. There
were 4 patients with cirrhosis who had postbaseline he-
moglobin values less than 10 g/dL; all were receiving
ribavirin. One patient (mentioned earlier) had a grade 3 ALT
increase (>5  upper limit of normal [ULN]). No patient had
a grade 2 ALT increase (an increase of >2.5 to 5  ULN) and
2 patients (both cirrhotic) had a grade 1 ALT increase
(increases to 1.25–2.5  ULN).Discussion
The development of oral DAAs represents a major
advance in the treatment of HCV in patients of all geno-
types. Currently available DAA combination regimens offer
SVR rates well over 90% overall and in most patient sub-
populations. Nevertheless, some patients do not achieve
SVR with existing regimens. Patients who have failed prior
treatment with ﬁrst-generation NS3/4A protease inhibitors
(eg, telaprevir, boceprevir, or simeprevir) may be re-treated
with ledipasvir-sofosbuvir, but patients who have been
treated unsuccessfully with a regimen that includes
an NS5A inhibitor have no approved re-treatment options.
In a previous trial, patients with genotype 1 HCV who
did not achieve SVR after 8 or 12 weeks of ledipasvir-
sofosbuvir–based regimens and subsequently were
re-treated with 24 weeks of ledipasvir-sofosbuvir had an
SVR12 rate of only 71%. In this population, the presence of
baseline NS5A RASs was associated with a higher rate of
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LIVERvirologic failure.18 In another small trial, 14 of 16 patients
(88%) who previously failed a daclatasvir-containing
regimen achieved SVR12 after re-treatment with
simeprevir-sofosbuvir for 12 weeks. Thirteen of the 16
patients had NS5A RASs at baseline, and, of these 13, 11
(85%) achieved SVR12. The 2 patients who did not achieve
SVR12 had Q30K and L31M substitutions as the dominant
viral populations at re-treatment baseline.19
In this open-label, phase 2 study, 12 weeks of treatment
with sofosbuvir-velpatasvir plus GS-9857 was safe and
highly effective in patients with HCV genotype 1, with and
without cirrhosis, who did not achieve SVR after prior
treatment with DAAs, including those who previously
received an NS5A inhibitor. In treatment-naive patients, the
8-week regimen was safe and effective, regardless of
cirrhosis status. Among the treatment-naive patients who
relapsed, the presence of baseline RASs appeared to have no
impact on treatment outcome. Treatment-emergent RASs by
deep sequencing with a 1% cut-off rate were rare (3 of 18;
17%), and no treatment-emergent RASs among relapsers
were detected with the 15% cut-off level. This is consistent
with the anticipated high barrier of resistance of the com-
bination therapy based on in vitro data.20
Treatment-naive patients without cirrhosis treated for 8
weeks achieved a SVR12 rate of 100%, which was higher
than results reported in a recent study of combining 3 DAAs
for treatment for the same population and treatment
duration.21 Treatment-naive patients with cirrhosis treated
for 8 weeks had lower SVR12 rates (81%–94%) than pa-
tients without cirrhosis. Larger studies will determine
whether this short duration is adequate for this patient
population.
One unexpected result in our trial was the apparent lack
of beneﬁt of the addition of ribavirin to sofosbuvir-
velpatasvir plus GS-9857 for treatment-naive patients with
cirrhosis. Although patients in this group receiving ribavirin
had a numerically lower rate of SVR12 than treatment-naive
patients with cirrhosis who received sofosbuvir-velpatasvir
plus GS-9857 without ribavirin (81% vs 94%), the conﬁ-
dence intervals overlap and it is likely that this reﬂects the
small sample sizes.
Factors limiting the interpretation of the results of this
trial include its small size and the uncontrolled, open-label
design. Although the trial enrolled only patients with ge-
notype 1 HCV, another trial of similar design has been
conducted to assess this combination regimen in patients
with non–genotype 1 HCV.
In conclusion, sofosbuvir-velpatasvir plus GS-9857 for 12
weeks provided a high rate of SVR12 (100%) and was well
tolerated in a group of patients currently without treatment
options—those with and without compensated cirrhosis
who have not achieved SVR after previous treatment with a
NS5A inhibitor-containing regimen. The addition of GS-9857
to sofosbuvir-velpatasvir also was safe in the treatment-
naive population, in whom it was effective in reducing the
treatment duration to 8 weeks while preserving a high rate
of SVR12. These 3 potent pangenotypic DAAs have been
co-formulated into a ﬁxed-dose combination tablet. The
phase 3 program will evaluate this ﬁxed-dose combination
Table 4.Safety
n (%)
Treatment naive DAA experienced
No cirrhosis Cirrhosis No cirrhosis Cirrhosis
SOF-VEL plus
GS-9857 for
6 wk (n ¼ 34)
SOF-VEL plus
GS-9857 for
8 wk (n ¼ 36)
SOF-VEL plus
GS-9857 for
8 wk (n ¼ 33)
SOF-VEL plus
GS-9857 plus RBV
for 8 wk (n ¼ 31)
SOF-VEL plus
GS-9857 for
12 wk (n ¼ 31)
SOF-VEL plus
GS-9857 for
12 wk (n ¼ 32)
Any adverse event 21 (62) 24 (68) 24 (73) 24 (77) 15 (48) 16 (50)
AEs leading to discontinuation
of all treatment
0 0 0 1 (3) 0 0
Deaths 0 0 1 (3) 0 0 0
AEs (occurring in 5%
of patients in any cohort)
Headache 11 (32) 7 (19) 7 (21) 9 (29) 4 (13) 5 (16)
Nausea 2 (6) 10 (28) 7 (21) 9 (29) 3 (10) 3 (9)
Fatigue 4 (12) 7 (19) 1 (3) 10 (32) 7 (23) 3 (9)
Diarrhea 4 (12) 6 (17) 2 (6) 3 (10) 3 (10) 3 (9)
Insomnia 5 (15) 1 (3) 0 3 (10) 2 (6) 0
Constipation 0 4 (11) 3 (9) 1 (3) 0 0
Nasopharyngitis 1 (3) 3 (8) 1 (3) 0 2 (6) 0
Anemia 0 0 0 7 (23) 0 0
Cough 1 (3) 3 (8) 0 0 1 (3) 1 (3)
Dizziness 2 (6) 2 (6) 1 (3) 1 (3) 0 0
Laboratory abnormalities
Hemoglobin level, <10.0 g/dL 0 0 0 4 (13) 0 0
Platelets, 25,000 to <50,000/mm3 0 0 1 (3) 0 0 2 (6)
INR, >2.0 to 3.0  ULN 0 0 1 (3) 0 0
ALT level, >5.00 to 10.00  ULN 0 0 0 1 (3) 0 0
Creatine kinase level,
10.0 to <20.0  ULN
0 1 (3) 0 0 0 0
Hyperglycemia, >250 to 500 mg/dL 0 0 1 (3) 1 (3) 0 2 (6)
Lipase, >5.0  ULN 1 (3) 0 0 4 (12) 0 1 (3)
Hyperbilirubinemia,
> 2.5 to 5.0  ULN
0 0 3 (10) 0 1 (3)
AE, adverse event.
Novem
ber
2016
SOF/VEL
Plus
GS-9857
in
HCV
GT
1
899
CLINICAL LIVER
900 Lawitz et al Gastroenterology Vol. 151, No. 5
CLINICAL
LIVERfor 8 weeks in treatment-naive patients and for 12 weeks in
DAA-experienced patients, including those who previously
have received an NS5A inhibitor.Supplementary Material
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